Abstract
Introduction
The proportion of the elderly is constantly increasing and by the year 2025 20% of the population will be above 65 years of age. With advanced age, subjects will develop multiple diseases and often need to take several drugs.
Discussion
This polypharmacy increases the risk for drug interactions and adverse effects. In addition, age-related physiological changes affect different biological systems and can contribute to alterations in pharmacokinetics and pharmacodynamics in older patients, which are more often seen in the frail than in the fit elderly. These features will complicate drug therapy in the elderly, and a careful dose titration is advisable. Furthermore, inappropriate drug prescription and non-adherence to medication represent common therapeutic challenges in elderly subjects. To date, there is no evidence of any effective antiageing agent.
Conclusion
This review summarizes present knowledge of age-related problems in drug action and their clinical implications for an increasingly important population.
Similar content being viewed by others
References
United Nations. World Population Aging 2007. http://www.un.org/esa/population/publications/WPA2007/wpp2007.htm. Accessed 26 August 2007
Aalami OO, Fang TD, Song HM, Nacamuli RP (2003) Physiological features of aging persons. Arch Surg 138:1068–1076
Schwartz JB (2007) The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin Pharmacol Ther 82:87–96
McLean AJ, Le Couteur DG (2004) Aging biology and geriatric clinical pharmacology. Pharmacol Rev 56:163–184
Stratton MA, Salinas RC (2003) Medication management in the elderly. J Okla State Med Assoc 96:116–122
Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA (2002) Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 287:337–344
Kennerfalk A, Ruigómez A, Wallander MA, Wilhelmsen L, Johansson S (2002) Geriatric drug therapy and healthcare utilization in the United Kingdom. Ann Pharmacother 36:797–803
Pizzuti R, Caffari B, Binkin N, Gruppo ARGENTO (2006) Prescription drugs and the elderly: results of the Argento study. Ig Sanita Publica 62:11–26
Wolff JL, Starfield B, Anderson G (2002) Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med 162:2269–2276
Doucet J, Queneau P (2005) Adverse drug reactions in the elderly. Bull Acad Natl Med 189:1693–1707; discussion 1708–1709
Herrlinger C, Klotz U (2001) Drug metabolism and drug interactions in the elderly. Best Pract Res Clin Gastroenterol 15:897–918
Vik SA, Hogan DB, Patten SB, Johnson JA, Romonko-Slack L, Maxwell CJ (2006) Medication nonadherence and subsequent risk of hospitalisation and mortality among older adults. Drugs Aging 23:345–356
Lau DT, Kasper JD, Potter DE, Lyles A, Bennett RG (2005) Hospitalization and death associated with potentially inappropriate medication prescriptions among elderly nursing home residents. Arch Intern Med 165:68–74
Spinewine A, Schmader KE, Barber N, Hughes C, Lapane KL, Swine C, Hanlon JT (2007) Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet 370:173–184
Woodhouse KW, O’Mahony MS (1997) Frailty and ageing. Age Ageing 26:245–246
Yancik R, Ershler W, Satariano W, Hazzard W, Cohen HJ, Ferrucci L (2007) Report of the national institute on aging task force on comorbidity. J Gerontol A Biol Sci Med Sci 62:275–280
Lash TL, Mor V, Wieland D, Ferrucci L, Satariano W, Silliman RA (2007) Methodology, design, and analytic techniques to address measurement of comorbid disease. J Gerontol A Biol Sci Med Sci 62:281–285
Boyd CM, Weiss CO, Halter J, Han KC, Ershler WB, Fried LP (2007) Framework for evaluating disease severity measures in older adults with comorbidity. J Gerontol A Biol Sci Med Sci 62:286–295
Karlamangla A, Tinetti M, Guralnik J, Studenski S, Wetle T, Reuben D (2007) Comorbidity in older adults: nosology of impairment, diseases, and conditions. J Gerontol A Biol Sci Med Sci 62:296–300
Varas-Lorenzo C, Rueda de Castro AM, Maguire A, Miret M (2006) Prevalence of glucose metabolism abnormalities and cardiovascular co-morbidity in the US elderly adult population. Pharmacoepidemiol Drug Saf 15:317–326
Braunstein JB, Anderson GF, Gerstenblith G, Weller W, Niefeld M, Herbert R, Wu AW (2003) Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol 42:1226–1233
van der Wel MC, Jansen RW, Bakx JC, Bor HH, Olderikkert MG, van Weel C (2007) Non-cardiovascular co-morbidity in elderly patients with heart failure outnumbers cardiovascular co-morbidity. Eur J Heart Fail 9:709–715
Cesari M, Onder G, Russo A, Zamboni V, Barillaro C, Ferrucci L, Pahor M, Bernabei R, Landi F (2006) Comorbidity and physical function: results from the aging and longevity study in the Sirente geographic area (ilSIRENTE study). Gerontology 52:24–32
Kadam U, Croft P; North Staffordshire GP Consortium Group (2007) Clinical multimorbidity and physical function in older adults: a record and health status linkage study in general practice. Fam Pract 24:412–419
Bretherton A, Day L, Lewis G (2003) Polypharmacy and older people. Nurs Times 99:54–55
Viktil KK, Blix HS, Moger TA, Reikvam A (2007) Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. Br J Clin Pharmacol 63:187–195
Fulton MM, Allen ER (2005) Polypharmacy in the elderly: a literature review. J Am Acad Nurse Pract 17:123–132
Rosholm JU, Holm EA; Dansk Selskab for Geriatri (2007) Polypharmacy in elderly patients – the eternal problem. The Danish Geriatric Society. Ugeskr Laeger 169:1104
Rajska-Neumann A, Wieczorowska-Tobis K (2007) Polypharmacy and potential inappropriateness of pharmaco-logical treatment among community-dwelling elderly patients. Arch Gerontol Geriatr 44[Suppl 1]:303–309
Lernfelt B, Samuelsson O, Skoog I, Landahl S (2003) Changes in drug treatment in the elderly between 1971 and 2000. Eur J Clin Pharmacol 59:637–644
Queneau P (2006) Pitfalls of polypharmacy, particularly in the elderly. Bull Mem Acad R Med Belg 161:408–421
Frazier SC (2005) Health outcomes and polypharmacy in elderly individuals: an integrated literature review. J Gerontol Nurs 31:4–11
Mallet L, Spinewine A, Huang A (2007) The challenge of managing drug interactions in elderly people. Lancet 370:185–191
Björkman IK, Fastbom J, Schmidt IK, Bernsten CB; Pharmaceutical Care of the Elderly in Europe Research (PEER) Group (2002) Drug-drug interactions in the elderly. Ann Pharmacother 36:1675–1681
Egger SS, Rätz Bravo AE, Hess L, Schlienger RG, Krähenbühl S (2007) Age-related differences in the prevalence of potential drug-drug interactions in ambulatory dyslipidaemic patients treated with statins. Drugs Aging 24:429–440
Dergal JM, Gold JL, Laxer DA, Lee MS, Binns MA, Lanctôt KL, Freedman M, Rochon PA (2002) Potential interactions between herbal medicines and conventional drug therapies used by older adults attending a memory clinic. Drugs Aging 19:879–886
Yoon SL, Schaffer SD (2006) Herbal, prescribed, and over-the-counter drug use in older women: prevalence of drug interactions. Geriatr Nurs 27:118–129
Pringle KE, Ahern FM, Heller DA, Gold CH, Brown TV (2005) Potential for alcohol and prescription drug interactions in older people. J Am Geriatr Soc 53:1930–1936
Lindblad CI, Hanlon JT, Gross CR, Sloane RJ, Pieper CF, Hajjar ER, Ruby CM, Schmader KE (2006) Clinically important drug-disease interactions and their prevalence in older adults. Clin Ther 28:1133–1143
Lindblad CI, Artz MB, Pieper CF, Sloane RJ, Hajjar ER, Ruby CM, Schmader KE, Hanlon JT (2005) Potential drug-disease interactions in frail, hospitalized elderly veterans. Ann Pharmacother 39:412–417
Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA (2003) Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 289:1652–1658
Doucet J, Chassagne P, Trivalle C, Landrin I, Pauty MD, Kadri N, Ménard JF, Bercoff E (1996) Drug–drug interactions related to hospital admissions in older adults: a prospective study of 1000 patients. J Am Geriatr Soc 44:944–948
Levy RH, Collins C (2007) Risk and predictability of drug interactions in the elderly. Int Rev Neurobiol 81:235–251
Zhan C, Correa-de-Araujo R, Bierman AS, Sangl J, Miller MR, Wickizer SW, Stryer D (2005) Suboptimal prescribing in elderly outpatients: potentially harmful drug-drug and drug–disease combinations. J Am Geriatr Soc 53:262–267
Lally F, Crome P (2007) Understanding frailty. Postgrad Med J 83:16–20
Ahmed N, Mandel R, Fain MJ (2007) Frailty: an emerging geriatic syndrome. Amer J Med 120:748–753
Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G (2004) Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci 59:255–263
Slaets JP (2006) Vulnerability in the elderly: frailty. Med Clin North Am 90:593–601
Cawthon PM, Marshall LM, Michael Y, Dam TT, Ensrud KE, Barrett-Connor E, Orwoll ES; for the Osteoporotic Fractures in Men Research Group (2007) Frailty in older men: prevalence, progression, and relationship with mortality. J Am Geriatr Soc 55:1216–1223
Ensrud KE, Ewing SK, Taylor BC, Fink HA, Stone KL, Cauley JA, Tracy JK, Hochberg MC, Rodondi N, Cawthon PM; the Study of Osteoporotic Fractures Research Group (2007) Frailty and risk of falls, fracture, and mortality in older women: the study of osteoporotic fractures. J Gerontol A Biol Sci Med Sci 62:744–751
Torpy JM, Lynm C, Glass RM (2006) JAMA patient page. Frailty in older adults. JAMA 296:2280
Walston J, McBurnie MA, Newman A, Tracy RP, Kop WJ, Hirsch CH, Gottdiener J, Fried LP; Cardiovascular Health Study (2002) Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: results from the Cardiovascular Health Study. Arch Intern Med 162:2333–2341
Cohen HJ, Harris T, Pieper CF (2003) Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. Am J Med 114:180–187
von Känel R, Dimsdale JE, Mills PJ, Ancoli-Israel S, Patterson TL, Mausbach BT, Grant I (2006) Effect of Alzheimer caregiving stress and age on frailty markers interleukin-6, C-reactive protein, and D-dimer. J Gerontol A Biol Sci Med Sci 61:963–969
Balducci L (2007) Aging, frailty, and chemotherapy. Cancer Control 14:7–12
Gobbens RJ, Luijkx KG, Wijnen-Sponselee MT, Schols JM (2007) Frail elderly. Identification of a population at risk. Tijdschr Gerontol Geriatr 38:65–76
Hanlon JT, Pieper CF, Hajjar ER, Sloane RJ, Lindblad CI, Ruby CM, Schmader KE (2006) Incidence and predictors of all and preventable adverse drug reactions in frail elderly persons after hospital stay. J Gerontol A Biol Sci Med Sci 61:511–515
Levers MJ, Estabrooks CA, Ross Kerr JC (2006) Factors contributing to frailty: literature review. J Adv Nurs 56:282–291
Marzetti E, Leeuwenburgh C (2006) Skeletal muscle apoptosis, sarcopenia and frailty at old age. Exp Gerontol 41:1234–1238
Janssen I (2006) Influence of sarcopenia on the development of physical disability: the Cardiovascular Health Study. J Am Geriatr Soc 54:56–62
Di Iorio A, Abate M, Di Renzo D, Russolillo A, Battaglini C, Ripari P, Saggini R, Paganelli R, Abate G (2006) Sarcopenia: age-related skeletal muscle changes from determinants to physical disability. Int J Immunopathol Pharmacol 19:703–719
Summerbell J, Wynne H, Hankey CR, Williams FM (1993) The effect of age and frailty upon blood esterase activities and their response to dietary supplementation. Br J Clin Pharmacol 36:399–404
Williams FM, Wynne H, Woodhouse KW, Rawlins MD (1989) Plasma aspirin esterase: the influence of old age and frailty. Age Ageing 18:39–42
Summerbell J, Yelland C, Woodhouse K (1990) The kinetics of plasma aspirin esterase in relation to old age and frailty. Age Ageing 19:128–130
Wynne HA, Cope LH, Herd B, Rawlins MD, James OF, Woodhouse KW (1990) The association of age and frailty with paracetamol conjugation in man. Age Ageing 19:419–424
Wynne HA, Yelland C, Cope LH, Boddy A, Woodhouse KW, Bateman DN (1993) The association of age and frailty with the pharmacokinetics and pharmacodynamics of metoclopramide. Age Ageing 22:354–359
Groen K, Horan MA, Roberts NA, Gulati RS, Miljkovic B, Jansen EJ, Paramsothy V, Breimer DD, van Bezooijen CF (1993) The relationship between phenazone (antipyrine) metabolite formation and theophylline metabolism in healthy and frail elderly women. Clin Pharmacokinet 25:136–144
Hughes CM (2004) Medication non-adherence in the elderly: how big is the problem? Drugs Aging 21:793–811
Black DM, Brand RJ, Greenlick M, Hughes G, Smith J (1987) Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program. J Gerontol 42:552–557
Kuzuya M, Endo H, Umegaki H, Nakao M, Niwa T, Kumagai T, Ushida Y, Nabeshima T, Iguchi A (2000) Factors influencing noncompliance with medication regimens in the elderly. Nippon Ronen Igakkai Zasshi 37:363–370
Kripalani S, Yao X, Haynes RB (2007) Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med 167:540–550
Topinková E, Fialová D, Carpenter GI, Bernabei R (2006) Cross-national comparison of drug compliance and non-compliance associated factors in the elderly with polypharmacotherapy. Cas Lek Ces 145:726–732
Bosworth HB, Voils CI, Potter GG, Steffens DC (2007) The effects of antidepressant medication adherence as well as psychosocial and clinical factors on depression outcome among older adults. Int J Geriatr Psychiatry 2007 June 12 (Epub ahead of print). PMID 17563920
Goeman DP, Douglass JA (2007) Optimal management of asthma in elderly patients: strategies to improve adherence to recommended interventions. Drugs Aging 24:381–394
Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487–497
Schneider MP, Locca JF, Bugnon O, Conzelmann M (2006) Drug compliance in the elderly: determinants and support. Rev Med Suisse 2:664–666, 669–670
Rottlaender D, Scherner M, Schneider T, Erdmann E (2007) Polypharmacy, compliance and non-prescription medication in patients with cardiovascular disease in Germany. Dtsch Med Wochenschr 132:139–144
Jackevicius CA, Mamdani M, Tu JV (2002) Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 288:462–467
Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J (2002) Long-term persistence in use of statin therapy in elderly patients. JAMA 288:455–461
Volmink J, Garner P (2007) WITHDRAWN: Interventions for promoting adherence to tuberculosis management. Cochrane Database Syst Rev 3:CD000010
Haynes RB, Yao X, Degani A, Kripalani S, Garg A, McDonald HP (2005) Interventions to enhance medication adherence. Cochrane Database Syst Rev 4:CD000011
Pastor Climente IP, Ortiz de Urbina Sandomingo V, Pérez Escoto I, Quintana Vargas I, Moreno Miralles A, Martínez Martínez M (2007) The introduction of a programme to improve the treatment compliance of institutionalised elderly patients. Farm Hosp 31:106–111
Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC (1991) Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. Arch Intern Med 151:1825–1832
Beers MH (1997) Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. Arch Intern Med 157:1531–1536
Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH (2003) Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 163:2716–2724
Laroche ML, Charmes JP, Merle L (2007) Potentially inappropriate medications in the elderly: a French consensus panel list. Eur J Clin Pharmacol 63:725–731
Pugh MJ, Hanlon JT, Zeber JE, Bierman A, Cornell J, Berlowitz DR (2006) Assessing potentially inappropriate prescribing in the elderly Veterans Affairs population using the HEDIS 2006 quality measure. J Manag Care Pharm 12:537–545
Gallagher P, Barry P, O’Mahony D (2007) Inappropriate prescribing in the elderly. J Clin Pharm Ther 32:113–121
Johnell K, Fastbom J, Rosén M, Leimanis A (2007) Inappropriate drug use in the elderly: a nationwide register-based study. Ann Pharmacother 41:1243–1248
Barry PJ, O’Keefe N, O’Connor KA, O’Mahony D (2006) Inappropriate prescribing in the elderly: a comparison of the Beers criteria and the improved prescribing in the elderly tool (IPET) in acutely ill elderly hospitalized patients. J Clin Pharm Ther 31:617–626
Landi F, Russo A, Liperoti R, Barillaro C, Danese P, Pahor M, Bernabei R, Onder G (2007) Impact of inappropriate drug use on physical performance among a frail elderly population living in the community. Eur J Clin Pharmacol 63:791–799
Page RL 2nd, Ruscin JM (2006) The risk of adverse drug events and hospital-related morbidity and mortality among older adults with potentially inappropriate medication use. Am J Geriatr Pharmacother 4:297–305
Zuckerman IH, Langenberg P, Baumgarten M, Orwig D, Byrns PJ, Simoni-Wastila L, Magaziner J (2006) Inappropriate drug use and risk of transition to nursing homes among community-dwelling older adults. Med Care 44:722–730
Fu AZ, Jiang JZ, Reeves JH, Fincham JE, Liu GG, Perri M 3rd (2007) Potentially inappropriate medication use and healthcare expenditures in the US community-dwelling elderly. Med Care 45:472–476
Passarelli MC, Jacob-Filho W, Figueras A (2005) Adverse drug reactions in an elderly hospitalised population: inappropriate prescription is a leading cause. Drugs Aging 22:767–777
Klarin I, Wimo A, Fastbom J (2005) The association of inappropriate drug use with hospitalisation and mortality: a population-based study of the very old. Drugs Aging 22:69–82
Laroche ML, Charmes JP, Nouaille Y, Picard N, Merle L (2007) Is inappropriate medication use a major cause of adverse drug reactions in the elderly? Br J Clin Pharmacol 63:177–186
Raivio MM, Laurila JV, Strandberg TE, Tilvis RS, Pitkälä KH (2006) Use of inappropriate medications and their prognostic significance among in-hospital and nursing home patients with and without dementia in Finland. Drugs Aging 23:333–343
Rochon PA, Gurwitz JH (1997) Optimising drug treatment for elderly people: the prescribing cascade. Br Med J 315:1096–1099
Gill SS, Mamdani M, Naglie G, Streiner DL, Bronskill SE, Kopp A, Shulman KI, Lee PE, Rochon PA (2005) A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med 165:808–813
Mangoni AA, Jackson SH (2004) Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 57:6–14
Hilmer SN, McLachlan AJ, Le Couteur DG (2007) Clinical pharmacology in the geriatric patient. Fundam Clin Pharmacol 21:217–230
Lotrich FE, Pollock BG (2005) Aging and clinical pharmacology: implications for antidepressants. J Clin Pharmacol 45:1106–1122
Aronow WS, Frishman WH, Cheng-Lai A (2007) Cardiovascular drug therapy in the elderly. Cardiol Rev 15:195–215
Feldman M (1997) The mature stomach. Still pumping out acid? JAMA 278:681–682
Haruma K, Kamada T, Kawaguchi H, Okamoto S, Yoshihara M, Sumii K, Inoue M, Kishimoto S, Kajiyama G, Miyoshi A (2000) Effect of age and Helicobacter pylori infection on gastric acid secretion. J Gastroenterol Hepatol 15:277–283
Nakamura K, Ogoshi K, Makuuchi H (2006) Influence of aging, gastric mucosal atrophy and dietary habits on gastric secretion. Hepatogastroenterology 53:624–628
Wiley JW (2002) Aging and neural control of the GI tract: III. Senescent enteric nervous system: lessons from extraintestinal sites and nonmammalian species. Am J Physiol Gastrointest Liver Physiol 283:G1020–G1026
Orr WC, Chen CL (2002) Aging and neural control of the GI tract: IV. Clinical and physiological aspects of gastrointestinal motility and aging. Am J Physiol Gastrointest Liver Physiol 283:G1226–G1231
Ciccocioppo R, Di Sabatino A, Luinetti O, Rossi M, Cifone MG, Corazza GR (2002) Small bowel enterocyte apoptosis and proliferation are increased in the elderly. Gerontology 48:204–208
Saltzman JR, Kowdley KV, Perrone G, Russell RM (1995) Changes in small-intestine permeability with aging. J Am Geriatr Soc 43:160–164
Kinirons MT, Crome P (1997) Clinical pharmacokinetic considerations in the elderly. An update. Clin Pharmacokinet 33:302–312
Zeeh J, Platt D (2002) The aging liver: structural and functional changes and their consequences for drug treatment in old age. Gerontology 48:121–127
Tateishi T, Fujimura A, Shiga T, Ohashi K, Ebihara A (1995) Influence of aging on the oxidative and conjugative metabolism of propranolol. Int J Clin Pharmacol Res 15:95–101
Anantharaju A, Feller A, Chedid A (2002) Aging Liver. A review. Gerontology 48:343–353
Davies RO, Gomez HJ, Irvin JD, Walker JF (1984) An overview of the clinical pharmacology of enalapril. Br J Clin Pharmacol 18[Suppl 2]:215S–229S
Dresser GK, Bailey DG, Carruthers SG (2000) Grapefruit juice-felodipine interaction in the elderly. Clin Pharmacol Ther 68:28–34
Muriel Villoria C, Pérez-Castejón Garrote JM, Sánchez Magro I, Neira Alvarez M (2007) Effectiveness and safety of transdermal buprenorphine for chronic pain treatment in the elderly: a prospective observational study. Med Clin (Barc) 128:204–210
Priano L, Gasco MR, Mauro A (2006) Transdermal treatment options for neurological disorders: impact on the elderly. Drugs Aging 23:357–375
Ramsay SE, Whincup PH, Shaper AG, Wannamethee SG (2006) The relations of body composition and adiposity measures to ill health and physical disability in elderly men. Am J Epidemiol 164:459–469
Tyagi R, Kapoor S, Kapoor AK (2005) Body composition and fat distribution pattern of urban elderly females, Delhi, India. Coll Antropol 29:493–498
Forbes GB, Reina JC (1970) Adult lean body mass declines with age: some longitudinal observations. Metabolism 19:653–663
Klotz U, Avant GR, Hoyumpa A, Schenker S, Wilkinson GR (1975) The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest 55:347–359
Hanratty CG, McGlinchey P, Johnston GD, Passmore AP (2000) Differential pharmacokinetics of digoxin in elderly patients. Drugs Aging 17:353–362
Mörike K, Schwab M, Klotz U (1997) Use of aminoglycosides in elderly patients. Pharmacokinetic and clinical considerations. Drugs Aging 10:259–277
Benet LZ, Hoener BA (2002) Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 71:115–121
Koyama H, Mori S, Sugioka N, Nishihara T, Nakajima K (2003) Age-related alteration of haloperidol-serum protein binding. J Pharm Pharmacol 55:77–83
Brenner SS, Herrlinger C, Dilger K, Mürdter TE, Hofmann U, Marx C, Klotz U (2003) Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. Clin Pharmacokinet 42:283–292
Krauwinkel WJ, Smulders RA, Mulder H, Swart PJ, Taekema-Roelvink ME (2005) Effect of age on the pharmacokinetics of solifenacin in men and women. Int J Clin Pharmacol Ther 43:227–238
Wynne H (2005) Drug metabolism and ageing. J Br Menopause Soc 11:51–56
Le Couteur DG, Fraser R, Hilmer S, Rivory LP, McLean AJ (2005) The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance. Clin Pharmacokinet 44:187–200
Durnas C, Loi CM, Cusack BJ (1990) Hepatic drug metabolism and aging. Clin Pharmacokinet 19:359–389
Le Couteur DG, McLean AJ (1998) The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet 34:359–373
James OF (1997) Parenchymal liver disease in the elderly. Gut 41:430–432
Schmucker DL (2001) Liver function and phase I drug metabolism in the elderly: a paradox. Drugs Aging 18:837–851
Wauthier V, Verbeeck RK, Calderon PB (2007) The effect of ageing on cytochrome p450 enzymes: consequences for drug biotransformation in the elderly. Curr Med Chem 14:745–757
Kinirons MT, O’Mahony MS (2004) Drug metabolism and ageing. Br J Clin Pharmacol 57:540–544
Woodhouse KW, James OF (1990) Hepatic drug metabolism and ageing. Br Med Bull 46:22–35
O’Connell MB, Frye RF, Matzke GR, St Peter JV, Willhite LA, Welch MR, Kowal P, LaValleur J (2006) Effect of conjugated equine estrogens on oxidative metabolism in middle-aged and elderly postmenopausal women. J Clin Pharmacol 46:1299–1307
Dorne JL, Walton K, Slob W, Renwick AG (2002) Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate? Food Chem Toxicol 40:1633–1656
Schmucker DL (1998) Aging and the liver: an update. J Gerontol A Biol Sci Med Sci 53:B315–B320
Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414–423
Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM (2004) The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 199:193–209
Kang D, Verotta D, Schwartz JB (2006) Population analyses of amlodipine in patients living in the community and patients living in nursing homes. Clin Pharmacol Ther 79:114–124
Frassetto LA, Poon S, Tsourounis C, Valera C, Benet LZ (2007) Effects of uptake and efflux transporter inhibition on erythromycin breath test results. Clin Pharmacol Ther 81:828–832
Kurnik D, Wood AJ, Wilkinson GR (2006) The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity. Clin Pharmacol Ther 80:228–234
Schwartz JB (2006) Erythromycin breath test results in elderly, very elderly, and frail elderly persons. Clin Pharmacol Ther 79:440–448
Dilger K, Hofmann U, Klotz U (2000) Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone. Clin Pharmacol Ther 67:512–520
Platten HP, Schweizer E, Dilger K, Mikus G, Klotz U (1998) Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. Clin Pharmacol Ther 63:552–560
Albrecht S, Ihmsen H, Hering W, Geisslinger G, Dingemanse J, Schwilden H, Schüttler J (1999) The effect of age on the pharmacokinetics and pharmacodynamics of midazolam. Clin Pharmacol Ther 65:630–639
Mangoni AA (2007) The impact of advancing age on P-glycoprotein expression and activity: current knowledge and future directions. Expert Opin Drug Metab Toxicol 3:315–320
Christians U (2004) Transport proteins and intestinal metabolism: P-glycoprotein and cytochrome P4503A. Ther Drug Monit 26:104–106
Christians U, Schmitz V, Haschke M (2005) Functional interactions between P-glycoprotein and CYP3A in drug metabolism. Expert Opin Drug Metab Toxicol 1:641–654
Brenner SS, Klotz U (2004) P-glycoprotein function in the elderly. Eur J Clin Pharmacol 60:97–102
Toornvliet R, van Berckel BN, Luurtsema G, Lubberink M, Geldof AA, Bosch TM, Oerlemans R, Lammertsma AA, Franssen EJ (2006) Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography. Clin Pharmacol Ther 79:540–548
Beck LH (1998) Changes in renal function with aging. Clin Geriatr Med 14:199–209
Lindeman RD, Tobin J, Shock NW (1985) Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 33:278–285
Rowe JW, Andres R, Tobin JD, Norris AH, Shock NW (1976) The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol 31:155–163
Fehrman-Ekholm I, Skeppholm L (2004) Renal function in the elderly (>70 years old) measured by means of iohexol clearance, serum creatinine, serum urea and estimated clearance. Scand J Urol Nephrol 38:73–77
Froissart M, Rossert J (2005) How to improve estimation of renal function in the elderly. Rev Prat 55:2223–2229
Fliser D, Franek E, Joest M, Block S, Mutschler E, Ritz E (1997) Renal function in the elderly: impact of hypertension and cardiac function. Kidney Int 51:1196–1204
Fliser D, Franek E, Ritz E (1997) Renal function in the elderly–is the dogma of an inexorable decline of renal function correct? Nephrol Dial Transplant 12:1553–1555
Laroche ML, Charmes JP, Marcheix A, Bouthier F, Merle L (2006) Estimation of glomerular filtration rate in the elderly: Cockcroft-Gault formula versus modification of diet in renal disease formula. Pharmacotherapy 26:1041–1046
Wasén E, Isoaho R, Mattila K, Vahlberg T, Kivelä SL, Irjala K (2004) Estimation of glomerular filtration rate in the elderly: a comparison of creatinine-based formulae with serum cystatin C. J Intern Med 256:70–78
Maftei ID, Cepoi V, Covic A (2007) Assessing renal function in elderly people. Rev Med Chir Soc Med Nat Iasi 111:27–38
Lewerin C, Ljungman S, Nilsson-Ehle H (2007) Glomerular filtration rate as measured by serum cystatin C is an important determinant of plasma homocysteine and serum methylmalonic acid in the elderly. J Intern Med 261:65–73
Corsonello A, Pedone C, Corica F, Mussi C, Carbonin P, Antonelli Incalzi R; Gruppo Italiano di Farmacovigilanza nell’Anziano (GIFA) Investigators (2005). Concealed renal insufficiency and adverse drug reactions in elderly hospitalized patients. Arch Intern Med 165:790–795
Sproule BA, Hardy BG, Shulman KI (2000) Differential pharmacokinetics of lithium in elderly patients. Drugs Aging 16:165–177
Raveh D, Kopyt M, Hite Y, Rudensky B, Sonnenblick M, Yinnon AM (2002) Risk factors for nephrotoxicity in elderly patients receiving once-daily aminoglycosides. Q J Med 95:291–297
Hirsch LJ, Arif H, Buchsbaum R, Weintraub D, Lee J, Chang JT, Resor SR Jr, Bazil CW (2007) Effect of age and comedication on levetiracetam pharmacokinetics and tolerability. Epilepsia 48:1351–1359
Perucca E (2007) Age-related changes in pharmacokinetics: predictability and assessment methods. Int Rev Neurobiol 81:183–199
Perucca E (2006) Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age. Clin Pharmacokinet 45:351–363
Boyd RA, Türck D, Abel RB, Sedman AJ, Bockbrader HN (1999) Effects of age and gender on single-dose pharmacokinetics of gabapentin. Epilepsia 40:474–479
Fliser D, Bischoff I, Hanses A, Block S, Joest M, Ritz E, Mutschler E (1999) Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. Eur J Clin Pharmacol 55:205–211
Meyer B, Traunmueller F, Bojic A, Locker G, Schmid R, Winkler S, Thalhammer F (2006) Single-dose pharmacokinetics of cefodizime in critically ill elderly patients. Int J Antimicrob Agents 27:335–338
Bressler R, Bahl JJ (2003) Principles of drug therapy for the elderly patient. Mayo Clin Proc 78:1564–1577
Jackson SH (1994) Pharmacodynamics in the elderly. J R Soc Med 87[Suppl 23]:5–7
Lichtman SM (2007) Pharmacokinetics and pharmacodynamics in the elderly. Clin Adv Hematol Oncol 5:181–182
Vuyk J (2003) Pharmacodynamics in the elderly. Best Pract Res Clin Anaesthesiol 17:207–218
Tobias D (2004) Age-related changes in pharmacokinetics and pharmacodynamics: a review. Consult Pharm 19:736–739
Shah RR (2004) Drug development and use in the elderly: search for the right dose and dosing regimen (Parts I and II). Br J Clin Pharmacol 58:452–469
Schwab M, Röder F, Aleker T, Ammon S, Thon KP, Eichelbaum M, Klotz U (2000) Psychotropic drug use, falls and hip fracture in the elderly. Aging (Milano) 12:234–239
Nomura K, Nakao M, Sato M, Yano E (2007) The long-term prescription of benzodiazepines, psychotropic agents, to the elderly at a university hospital in Japan. Tohoku J Exp Med 212:239–246
Barberá T, Avellana JA, Moreno L (2007) Are benzodiazepines correctly used in the elderly? Rev Clin Esp 207:138–140
Mottram P, Wilson K, Strobl J (2006) Antidepressants for depressed elderly. Cochrane Database Syst Rev 25:CD003491
Sophie S (2007) Anaesthesia for the elderly patient. J Pak Med Assoc 57:196–201
Tsui BC, Wagner A, Finucane B (2004) Regional anaesthesia in the elderly: a clinical guide. Drugs Aging 21:895–910
Osman ES, Khafagy HF, Radwan KG, Desouky AM (2007) Role of cholinesterase activity on pharmacodynamics of mivacurium preceded by pancuronium in elderly and young adults. J Egypt Soc Parasitol 37:243–255
Mapleson WW (1996) Effect of age on MAC in humans: a meta-analysis. Br J Anaesth 76:179–185
Nickalls RW, Mapleson WW (2003) Age-related iso-MAC charts for isoflurane, sevoflurane and desflurane in man. Br J Anaesth 91:170–174
Vestal RE, Wood AJ, Shand DG (1979) Reduced beta-adrenoceptor sensitivity in the elderly. Clin Pharmacol Ther 26:181–186
Connolly MJ, Crowley JJ, Charan NB, Nielson CP, Vestal RE (1995) Impaired bronchodilator response to albuterol in healthy elderly men and women. Chest 108:401–406
Parker AL (2004) Aging does not affect beta-agonist responsiveness after methacholine-induced bronchoconstriction. J Am Geriatr Soc 52:388–392
Elliott HL (1988) Alpha 1-adrenoceptor responsiveness: the influence of age. J Cardiovasc Pharmacol 12[Suppl 8]:S116–S123
Nair BR (2002) Evidence based medicine for older people: available, accessible, acceptable, adaptable? Aust J Ageing 21:58–60
Hernández-Díaz S, Rodríguez LA (2000) Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 160:2093–2099
Routledge PA, O’Mahony MS, Woodhouse KW (2004) Adverse drug reactions in elderly patients. Br J Clin Pharmacol 57:121–126
Onder G, Pedone C, Landi F, Cesari M, Della Vedova C, Bernabei R, Gambassi G (2002) Adverse drug reactions as cause of hospital admissions: results from the Italian Group of Pharmacoepidemiology in the Elderly (GIFA). J Am Geriatr Soc 50:1962–1968
Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. Br Med J 329:15–19
van der Hooft CS, Sturkenboom MC, van Grootheest K, Kingma HJ, Stricker BH (2006) Adverse drug reaction-related hospitalisations: a nationwide study in The Netherlands. Drug Safety 29:161–168
Zargarzadeh AH, Emami MH, Hosseini F (2007) Drug-related hospital admissions in a generic pharmaceutical system. Clin Exp Pharmacol Physiol 34:494–498
Jenerowicz D, Czarnecka-Operacz M, Górecka A, Stawny M (2006) Drug-related hospital admissions–an overview of frequency and clinical presentation. Acta Pol Pharm 63:395–399
Hitchen L (2006) Adverse drug reactions result in 250,000 UK admissions a year. Br Med J 332:1109
Burgess CL, Holman CD, Satti AG (2005) Adverse drug reactions in older Australians, 1981–2002. Med J Aust 182:267–270
Zhang M, Holman CD, Preen DB, Brameld K (2007) Repeat adverse drug reactions causing hospitalization in older Australians: a population-based longitudinal study 1980–2003. Br J Clin Pharmacol 63:163–170
Beyth RJ, Shorr RI (1999) Epidemiology of adverse drug reactions in the elderly by drug class. Drugs Aging 14:231–239
Stillman MJ, Stillman MT (2007) Choosing nonselective NSAIDs and selective COX-2 inhibitors in the elderly. A clinical use pathway. Geriatrics 62:26–34
Lagunes-Espinosa AL, Peralta-Pedrero ML, Rodríguez-Moctezuma R, López-Carmona JM, Ibarra-Vicens E, Cruz-Avelar A, Murguía-Miranda C (2007) Characterizing the prescription of non-steroidal anti-inflammatory drugs among the elderly. Gac Med Mex 143:5–9
Tarone RE, Blot WJ, McLaughlin JK (2004) Nonselective nonaspirin nonsteroidal anti-inflammatory drugs and gastrointestinal bleeding: relative and absolute risk estimates from recent epidemiologic studies. Am J Ther 11:17–25
Lanas A, Ferrandez A (2007) Inappropriate prevention of NSAID-induced gastrointestinal events among long-term users in the elderly. Drugs Aging 24:121–131
González-Juanatey JR, Rivera J, Gabriel Sánchez R, Reviriego Almohalla B, Casimiro C (2006) Effects of NSAID on blood pressure among hypertensive patients with a high cardiovascular risk. An Med Intern 23:420–427
Babbar JP (2007) Polypharmacy and adverse drug reactions. Psychiatr Serv 58:1011
Centorrino F, Goren JL, Hennen J, Salvatore P, Kelleher JP, Baldessarini RJ (2004) Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry 161:700–706
Nguyen JK, Fouts MM, Kotabe SE, Lo E (2006) Polypharmacy as a risk factor for adverse drug reactions in geriatric nursing home residents. Am J Geriatr Pharmacother 4:36–41
Burton DG, Allen MC, Bird JL, Faragher RG (2005) Bridging the gap: ageing, pharmacokinetics and pharmacodynamics. J Pharm Pharmacol 57:671–679
Kannus P, Khan KM, Lord SR (2006) Preventing falls among elderly people in the hospital environment. Falls and related injuries among seniors are a compelling ongoing priority for Australian health research. Med J Aust 184:372–373
Heinze C, Halfens RJ, Dassen T (2007) Falls in German in-patients and residents over 65 years of age. J Clin Nurs 16:495–501
Akyol AD (2007) Falls in the elderly: what can be done? Int Nurs Rev 54:191–196
Prat-González I, Fernández-Escofet E, Martínez-Bustos S (2007) Assessment of risk of falls in the elderly through a screening protocol in primary care. Enferm Clin 17:128–133
Zanocchi M, Pilon S, Speme S, Nicola E, Corsinovi L, Ponte E, Cerrato F, Luppino A, Martinelli E, Margolicci A, Molaschi M (2004) Falls in hospitalized elderly patients: incidence and risk factors. Recenti Prog Med 95:570–574
Daal JO, van Lieshout JJ (2005) Falls and medications in the elderly. Neth J Med 63:91–96
Walker PC, Alrawi A, Mitchell JF, Regal RE, Khanderia U (2005) Medication use as a risk factor for falls among hospitalized elderly patients. Am J Health Syst Pharm 62:2495–2499
Ziere G, Dieleman JP, Hofman A, Pols HA, van der Cammen TJ, Stricker BH (2006) Polypharmacy and falls in the middle age and elderly population. Br J Clin Pharmacol 61:218–223
Allain H, Bentué-Ferrer D, Polard E, Akwa Y, Patat A (2005) Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly: a comparative review. Drugs Aging 22:749–765
Finkel T, Holbrook NJ (2000) Oxidants, oxidative stress and the biology of ageing. Nature 408:239–247
Harman D (2006) Free radical theory of aging: an update: increasing the functional life span. Ann N Y Acad Sci 1067:10–21
Butler RN, Fossel M, Harman SM, Heward CB, Olshansky SJ, Perls TT, Rothman DJ, Rothman SM, Warner HR, West MD, Wright WE (2002) Is there an antiaging medicine? J Gerontol A Biol Sci Med Sci 57:B333–B338
Fisher A, Morley JE (2002) Antiaging medicine: the good, the bad, and the ugly. J Gerontol A Biol Sci Med Sci 57:M636–M639
Olshansky SJ, Hayflick L, Perls TT (2004) Introduction: anti-aging medicine: the hype and the reality – part II. J Gerontol Series A: Bio Sci Med Sci 59A:B649–B651
Scientific American (2002) The truth about human aging. http://www.sciam.com/article.cfm?articleID=0004F171-FE1E-1CDF-B4A8809EC588EEDF. Accessed 9 September 2007
National Vital Statistics Reports. Vol. 53, No. 6, November 10, 2004. http://www.cdc.gov/nchs/data/dvs/nvsr53_06t12.pdf. Accessed 3 September 2007
Grossman T (2005) Latest advances in antiaging medicine. Keio J Med 54:85–94
Klotz U (2007) The elderly–a challenge for appropriate drug treatment. Eur J Clin Pharmacol (in press)
Acknowledgements
This work was supported by the Robert Bosch Foundation Stuttgart, Germany.
Conflict of interest statement
The authors declare no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shi, S., Mörike, K. & Klotz, U. The clinical implications of ageing for rational drug therapy. Eur J Clin Pharmacol 64, 183–199 (2008). https://doi.org/10.1007/s00228-007-0422-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-007-0422-1